347 related articles for article (PubMed ID: 12948013)
21. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
22. The pharmacological role of P-glycoprotein in the intestinal epithelium.
Van Asperen J; Van Tellingen O; Beijnen JH
Pharmacol Res; 1998 Jun; 37(6):429-35. PubMed ID: 9695116
[TBL] [Abstract][Full Text] [Related]
23. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
Miyake T; Tsutsui H; Haraya K; Tachibana T; Morimoto K; Takehara S; Ayabe M; Kobayashi K; Kazuki Y
Br J Pharmacol; 2021 Nov; 178(21):4335-4351. PubMed ID: 34232502
[TBL] [Abstract][Full Text] [Related]
24. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
[TBL] [Abstract][Full Text] [Related]
25. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.
Igel S; Drescher S; Mürdter T; Hofmann U; Heinkele G; Tegude H; Glaeser H; Brenner SS; Somogyi AA; Omari T; Schäfer C; Eichelbaum M; Fromm MF
Clin Pharmacokinet; 2007; 46(9):777-85. PubMed ID: 17713975
[TBL] [Abstract][Full Text] [Related]
26. Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine.
Akazawa T; Yoshida S; Ohnishi S; Kanazu T; Kawai M; Takahashi K
Drug Metab Dispos; 2018 Nov; 46(11):1497-1506. PubMed ID: 30135242
[TBL] [Abstract][Full Text] [Related]
27. Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine.
Yumoto R; Murakami T; Takano M
Pharm Res; 2003 May; 20(5):765-71. PubMed ID: 12751632
[TBL] [Abstract][Full Text] [Related]
28. Effect of hydroxyzine on the transport of etoposide in rat small intestine.
Kan WM; Liu YT; Hsiao CL; Shieh CY; Kuo JH; Huang JD; Su SF
Anticancer Drugs; 2001 Mar; 12(3):267-73. PubMed ID: 11290874
[TBL] [Abstract][Full Text] [Related]
29. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
30. Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical models.
Riede J; Umehara KI; Schweigler P; Huth F; Schiller H; Camenisch G; Poller B
Eur J Pharm Sci; 2019 Apr; 132():132-141. PubMed ID: 30857914
[TBL] [Abstract][Full Text] [Related]
31. Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters.
Ashmawy SM; El-Gizawy SA; El Maghraby GM; Osman MA
J Pharm Pharmacol; 2019 Mar; 71(3):362-370. PubMed ID: 30362574
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
33. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
34. P-Glycoprotein attenuates brain uptake of substrates after nasal instillation.
Graff CL; Pollack GM
Pharm Res; 2003 Aug; 20(8):1225-30. PubMed ID: 12948020
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
36. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
37. Impact of In Vitro Passive Permeability in a P-gp-transfected LLC-PK1 Model on the Prediction of the Rat and Human Unbound Brain-to-Plasma Concentration Ratio.
Nicolaï J; Chapy H; Gillent E; Saunders K; Ungell AL; Nicolas JM; Chanteux H
Pharm Res; 2020 Aug; 37(9):175. PubMed ID: 32856111
[TBL] [Abstract][Full Text] [Related]
38. In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay.
Rabba AK; Si L; Xue K; Li M; Li G
J Pharm Pharm Sci; 2011; 14(2):138-47. PubMed ID: 21733405
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
[TBL] [Abstract][Full Text] [Related]
40. Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells.
Tsukura Y; Mori M; Hirotani Y; Ikeda K; Amano F; Kato R; Ijiri Y; Tanaka K
Biol Pharm Bull; 2007 Oct; 30(10):1982-6. PubMed ID: 17917278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
